HR Execs on the Move

Oncopeptides

www.oncopeptides.com

 
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Spinal Elements

Spinal Elements, Inc. is an innovative spine technology company that delivers new standards in spine surgery. Spinal Elements, previously Amendia.

University Compounding Pharmacy

University Compounding Pharmacy is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kyowa Hakko Kirin Pharma

Kyowa Hakko Kirin Pharma is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BVI

Beaver-Visitec International (BVI) is a highly regarded ophthalmic device manufacturer offering a broad range of single use instruments & custom procedure packs

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.